| __timestamp | Alkermes plc | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 447875000 | 14400000 |
| Thursday, January 1, 2015 | 483393000 | 33800000 |
| Friday, January 1, 2016 | 519270000 | 35900000 |
| Sunday, January 1, 2017 | 567637000 | 1254000 |
| Monday, January 1, 2018 | 601826000 | 4889000 |
| Tuesday, January 1, 2019 | 693218000 | 7400000 |
| Wednesday, January 1, 2020 | 572904000 | 10100000 |
| Friday, January 1, 2021 | 603913000 | 14300000 |
| Saturday, January 1, 2022 | 218108000 | 23200000 |
| Sunday, January 1, 2023 | 253037000 | 39700000 |
| Monday, January 1, 2024 | 245331000 | 34000000 |
Unlocking the unknown
In the ever-evolving landscape of biopharmaceuticals, understanding cost dynamics is crucial. Over the past decade, Alkermes plc and Neurocrine Biosciences, Inc. have showcased contrasting trends in their cost of revenue. From 2014 to 2023, Alkermes experienced a significant fluctuation, peaking in 2019 with a 55% increase from 2014, before dropping sharply by 68% in 2022. Meanwhile, Neurocrine Biosciences, Inc. demonstrated a steady upward trajectory, with costs rising by over 175% from 2014 to 2023. This divergence highlights the strategic differences in operational management and market adaptation between the two companies. As the biopharma sector continues to innovate, these insights offer a glimpse into the financial strategies that drive success in a competitive market.
Cost Insights: Breaking Down Teva Pharmaceutical Industries Limited and Alkermes plc's Expenses
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Alkermes plc
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Bio-Techne Corporation and Alkermes plc
Analyzing Cost of Revenue: Pharming Group N.V. and Alkermes plc
Cost of Revenue: Key Insights for Alkermes plc and Ligand Pharmaceuticals Incorporated